Quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is emerging as a valuable tool for assessing tumor and parenchymal perfusion in the liver, playing a developing role in locoregional therapies (LRTs) for hepatocellular carcinoma (HCC). This review explores the conceptual underpinnings and early investigational stages of DCE-MRI for LRTs, including thermal ablation, transarterial chemoembolization (TACE), and transarterial radioembolization (TARE). Preclinical and early-phase studies suggest that DCE-MRI may offer valuable insights into HCC tumor microvasculature, treatment response, and therapy planning. In thermal ablation therapies, DCE-MRI provides a quantitative measurement of tumor microvasculature and perfusion, which can guide more effective energy delivery and estimation of ablation margins. For TACE, DCE-MRI parameters are proving their potential to describe treatment efficacy and predict recurrence, especially when combined with adjuvant therapies. In ⁹⁰Y TARE, DCE-MRI shows promise for refining dosimetry planning by mapping tumor blood flow to improve microsphere distribution. However, despite these promising applications, there remains a profound gap between early investigational studies and clinical translation. Current quantitative DCE-MRI research is largely confined to phantom models and initial feasibility assessments, with robust retrospective data notably lacking and prospective clinical trials yet to be initiated. With continued development, DCE-MRI has the potential to personalize LRT treatment approaches and serve as an important tool to enhance patient outcomes for HCC.